Dzoanet, as you described it, PTX-200 might be considered as an "ingredient" of Cell-Pryme-M and CellPryme-A.
CellPryme-M is a manufacturing step in the preparation of cell therapies in which PTX-200, as an example of an AKT inhibitor and PH domain inhibitor, may be used in a medium in which cells are cultured.
CellPryme-A is an adjuvant therapy for cellular therapy in which PTX-200 may be used, but likely in combination with a checkpoint inhibitor.
These are new inventions and therefore require new names. I don’t have a problem with that.
If the supposition of PTX playing a crucial role in both CellPryme-M and CellPryme-A is correct, as a shareholder, I’m happy to see the company very cleverly working to derive maximum value from an existing asset.
- Forums
- ASX - By Stock
- PTX
- Ann: AGM Presentation
Ann: AGM Presentation, page-33
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.3¢ |
Change
0.001(2.38%) |
Mkt cap ! $34.62M |
Open | High | Low | Value | Volume |
4.2¢ | 4.5¢ | 4.0¢ | $86.84K | 2.054M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 205859 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 9166 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 205859 | 0.041 |
12 | 863078 | 0.040 |
7 | 548470 | 0.039 |
2 | 215000 | 0.038 |
2 | 67000 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 9166 | 1 |
0.046 | 197002 | 2 |
0.047 | 600000 | 2 |
0.048 | 177391 | 2 |
0.049 | 155000 | 2 |
Last trade - 15.59pm 14/06/2024 (20 minute delay) ? |
|
|||||
Last
4.3¢ |
  |
Change
0.001 ( 2.38 %) |
|||
Open | High | Low | Volume | ||
4.2¢ | 4.5¢ | 4.0¢ | 1474304 | ||
Last updated 15.40pm 14/06/2024 ? |
Featured News
PTX (ASX) Chart |